A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
Recruiting
The study will look at how well CagriSema helps people lower their blood sugar and body weight. CagriSema is a new weekly medicine that combines two medicines called semaglutide and cagrilintide. CagriSema will be compared to the two medicines semaglutide and cagrilintide, when they are taken alone. CagriSema will also be compared to a "dummy" medicine without any active ingredient. The study will be done in participants who have type 2 diabetes. Participants will take the study medicine togethe... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/29/2023
Locations: Novo Nordisk Investigational Site, Boise, Idaho +1 locations
Conditions: Type 2 Diabetes Mellitus
A Study to Test Whether BI 456906 Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
Recruiting
This study is open to adults who are at least 18 years old and have a body mass index of 27 kg/m² or more. People can take part if they have type 2 diabetes and if they are currently being treated only with diet and exercise or with specific diabetes medications. Only people who have previously not managed to lose weight by changing their diet can participate. The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesit... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
11/27/2023
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity, Diabetes Mellitus, Type 2
Diamyd Administered Into Lymph Nodes in Individuals Recently Diagnosed With Type 1 Diabetes, Carrying the HLA DR3-DQ2 Haplotype
Recruiting
The objective of DIAGNODE-3 is to evaluate the efficacy and safety of three intranodal injections of 4 μg of Diamyd compared to placebo, along with oral Vitamin D supplementation, to preserve endogenous beta cell function and influence glycemic parameters in adolescent and adults recently diagnosed with T1D carrying the HLA DR3-DQ2 haplotype.
Gender:
All
Ages:
Between 12 years and 28 years
Trial Updated:
11/17/2023
Locations: Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Autoimmune Diseases, Immune System Disease, Diabetes, Juvenile Diabetes, Endocrine System Diseases, Insulin Dependent Diabetes Mellitus 1, Glucose Metabolism Disorders, Metabolic Disease, Autoimmune Diabetes, Dysglycemia
Evaluation of the MiniMed™ 780G System in Type 1 Adult and Pediatric Subjects Utilizing Insulin Fiasp®
Recruiting
This global study (US, Canada, and Australia) will evaluate the safety and effectiveness of the MiniMed 780G system in type 1 adult and pediatric subjects utilizing Fiasp (insulin aspart injection) in a home setting.
Gender:
All
Ages:
Between 7 years and 80 years
Trial Updated:
11/14/2023
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Type 1 Diabetes
A Randomized Trial Evaluating Control-IQ Technology in Adults With Type 2 Diabetes
Recruiting
A randomized controlled trial (RCT) to assess the safety and efficacy of use of Control-IQ technology in adults with type 2 diabetes using basal-bolus insulin therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
11/13/2023
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Type 2 Diabetes Treated With Insulin
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
All
Ages:
Between 30 years and 80 years
Trial Updated:
11/08/2023
Locations: Boise Kidney and Hypertension Institute, Boise, Idaho +1 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Afrezza® INHALE-1 Study in Pediatrics
Recruiting
INHALE-1 is a Phase 3, open-label, randomized clinical study evaluating the efficacy and safety of Afrezza in combination with a basal insulin (i.e., the Afrezza group) versus insulin aspart, insulin lispro or insulin glulisine in combination with a basal insulin (i.e., the Rapid-acting Insulin Analog [RAA] injection group) in pediatric subjects with type 1 or type 2 diabetes mellitus. Following 26 weeks of randomized treatment (i.e., Afrezza or RAA injection combined with a basal insulin), all... Read More
Gender:
All
Ages:
Between 4 years and 17 years
Trial Updated:
11/07/2023
Locations: Rocky Mountain Clinical Research, Idaho Falls, Idaho
Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
Recruiting
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes. The study will last about 77 weeks and may include up to 22 visits.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Solaris Clinical Research, Meridian, Idaho
Conditions: Obesity, Overweight, Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone
Recruiting
The main purpose of this study is to determine safety and efficacy of orforglipron compared with placebo in adult participants with type 2 diabetes and inadequate glycemic control with diet and exercise alone. The study will last approximately 54 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Family First Medical Center, Idaho Falls, Idaho
Conditions: Type 2 Diabetes
A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin
Recruiting
The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
10/18/2023
Locations: Northwest Clinical Trials, Boise, Idaho +1 locations
Conditions: Type 2 Diabetes
A Study of Nasal Glucagon (LY900018) in Pediatric Participants With Type 1 Diabetes
Recruiting
The main purpose of this study is to evaluate the safety and tolerability of a study drug called nasal glucagon (Baqsimi) in pediatric participants with type 1 diabetes (T1D) aged 1 to less than 4 years. Blood tests will be performed to check how much nasal glucagon gets into the bloodstream. Blood sugar will also be measured to understand the effect of the drug on blood sugar levels. The study consists of a screening period up to 35 days before dosing, 1 day when a dose of nasal glucagon will b... Read More
Gender:
All
Ages:
Between 1 year and 4 years
Trial Updated:
10/17/2023
Locations: St. Luke's Regional Medical Center, Boise, Idaho
Conditions: Type 1 Diabetes
Evaluation of the Advanced Hybrid Closed Loop (AHCL) System in Type 1 Adults and Pediatrics Utilizing Lyumjev®
Recruiting
This US study will evaluate the safety and effectiveness of utilizing insulin Lyumjev® lispro-aabc in the MiniMed™ 780G System in Type 1 adult and pediatric subjects in a home setting to support product and system labeling.
Gender:
All
Ages:
Between 7 years and 80 years
Trial Updated:
10/09/2023
Locations: Rocky Mountain, Idaho Falls, Idaho
Conditions: Type 1 Diabetes